ArticleMolecular medicine reports2026
Effects of β‑hydroxybutyrate on restoring autophagic flux and mitochondrial function in macrophages exposed to oxidized low‑density lipoprotein.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis represents a major risk factor contributing to the development and advancement of cardiovascular diseases. The present study aimed to investigate the role of impaired autophagy and mitochondrial dysfunction in THP‑1 macrophages induced by oxidized low‑density lipoprotein (ox‑LDL), a key factor in atherosclerosis and cardiovascular disease. The molecular mechanism underlying the contribution of ox‑LDL to macrophage dysfunction is poorly understood. The present study aimed to determine whether β‑hydroxybutyrate (BHB) protects autophagic and mitochondrial function in THP‑1 macrophages exposed to ox‑LDL. Using cell culture, western blotting, autophagy detection assay and measurement of mitochondrial membrane potential, the present study evaluated the effect of BHB on autophagic flux and mitochondrial integrity. Ox‑LDL treatment markedly increased p62 protein levels and decreased LC3‑II/LC3‑I ratios, indicating impaired autophagy. BHB decreased p62 levels, increased LC3‑II/LC3‑I ratios and restored autophagic flux (shown by increased autophagosome numbers) and improved mitochondrial membrane potential. In addition, BHB downregulated STAT4, which was upregulated by ox‑LDL, suggesting a signaling pathway through which BHB exerts its protective effect. The present findings demonstrate that BHB enhances autophagic activity and mitochondrial function in THP‑1 macrophages under ox‑LDL stress, highlighting its potential as a novel therapeutic agent for metabolic and cardiovascular disease. Future studies should examine in vivo applications and the broader implications of BHB in atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.